Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

Applied Health Economics and Health Policy

Volumn 9, Issue 4, 2011, Pages 259-273

  Mueller, Dirk ^a   Gandjour, Afschin ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Alendronic acid; Budget impact analysis; Cost utility; Postmenopausal osteoporosis; Radiography

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; BUDGET; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOREARM FRACTURE; GERMANY; HEALTH INSURANCE; HIDDEN MARKOV MODEL; HIP FRACTURE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; FRACTURES, BONE; GERMANY; HUMANS; MARKOV CHAINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SECONDARY PREVENTION; TERTIARY PREVENTION;

EID: 79959430608     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11587360-000000000-00000     Document Type: Article

References (70)

1. WHO. Prevention and management of osteoporosis: report of a WHO Scientific Group. WHO technical report series, no. 921 [online]. Available from URL: http://apps.who.int/ bookorders/anglais/detart1.jsp?sesslan=1&codlan= 1&cod col=10&codcch=921 [Accesed 2010 Aug 2]
2. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998; 8 (6): 611-7 (Pubitemid 28566979)
3. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007 Mar; 22 (3): 465-75 (Pubitemid 46797130)
4. Dequeker J. Strategies for prevention and treatment of osteoporosis at the primary, secondary, and tertiary level in Leuven, Belgium. Clin Calcium 2001 Apr; 11 (4): 477-88
5. German osteology umbrella organization DVO. Prophylaxe, Diagnostik und Therapie der Osteoporose. S3-Leitlinie des Dachverbandes der deutschsprachigen wissenschaftlichen osteologischen Gesellschaften (2006) [online]. Available fromURL: http://www.dv-osteologie.org/dvo-leitlinien/dvoleitlinie- 2009 [Accessed 2010 Feb 20].
6. National Osteoporosis Foundation. NOFs clinicians guide to prevention and treatment of osteoporosis [online]. Available from URL: http://www.nof.org/ professionals/ clinical-guidelines [Accessed 2011 May 14].
7. National Institute for Health and Clinical Excellence. Osteoporosis: secondary prevention. The clinical effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women. London:NICE, 2005 [online]. Available from URL: http://www.nice.org. uk/guidance/index.jsp?action=byID&o=11550 [Accessed 2010 Jun 11].
8. Lühmann D, Kohlmann T, Raspe H. Use of bone densitometry in the framework of prevention and therapy of osteoporosis: example of a systematic evaluation (health technology assessment). Z Arztl Fortbild Qualitatssich 2000 Aug; 94 (6): 475-81
9. Federal Joint Commitee (GBA). Osteodensitometrie. Zusammenfassender Bericht des Arbeitsausschusses ,,Ärztliche Behandlung des Bundesausschusses der Ärzte und Krankenkassen über die Beratungen des Jahres 1999 zur Bewertung der Osteodensitometrie gemäX y135 Abs. 1 SGB V (2000) [online]. Available from URL: http://www.g-ba. de/institution/sys/suche/?search-query= densitometrie [Accessed 2010 Apr 9]
10. Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 2008; 26 (6): 513-36 (Pubitemid 351704859)
11. Müller D, Gandjour A. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women. Value Health 2009 Nov 12 (8): 1106-17.
12. Kanis JA, Adams J, Borgström F, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008 Jan; 42 (1): 4-15
13. Jansen JP,Gaugris S, Bergman G, et al. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and the Netherlands. Curr Med Res Opin 2008 Mar; 24 (3): 671-84 (Pubitemid 351428978)
14. National Association of Statutory Health Insurance Funds. Statutory health insurance [online]. Available from URL: http://www.gkv-spitzenverband.de/ GKV-was-ist-das.gkvnet [Accessed 2011 May 14].
15. Zentralinstitut für Kassenärztliche Versorgung. ZI-ADTPanel Nordrhein, Patienten-/Praxisstichprobe: IV/ 2005 [online]. Available from URL: http://www.zi-berlin.de/ cms/projekte/adt-panel/ [Accessed 2011 May 14].
16. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996 Oct 16; 276 (15): 1253-8 (Pubitemid 26337709)
17. Federal Statistical Office Germany (DESTATIS). Consumer price index for Germany (2007) [online]. Available from URL: http://www.destatis.de/jetspeed/ portal/cms/Sites/de statis/Internet/DE/Navigation/Statistiken/Preise/Verbrauch erpreise/Verbraucherpreise,templateId=renderPrint.psml-nnn=true [Accessed 2009 Dec 12]
18. Zethraeus N, BorgströmF, StrömO, et al. Cost-effectiveness of the treatment and prevention of osteoporosis: a review of the literature and a reference model. Osteoporos Int 2007; 18: 9-23 (Pubitemid 44885492)
19. Felsenberg D, Silman AJ, Lunt M, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17: 716-23
20. Federal Statistical Office Germany (DESTATIS). Diagnosedaten der Krankenhauspatientinnen u. patienten (einschl. Sterbe- u. Stundenfälle) Fachserie 12 Reihe 6.2.1 (2003) [online]. Available from URL: https://www-ec. destatis.de/csp/shop/sfg/bpm.html.cms.cBroker.cls?cmspath =struktur,vollanzeige. csp&ID=1023509 [Accessed 2009 Dec 8]
21. Singer BR, McLauchlan GJ, Robinson CM, et al. Epidemiology of fractures in 15 000 adults: the influence of age and gender. J Bone Joint Surg Br 1998; 80: 243-8
22. Browner WS, Seeley DG, Vogt TM, et al. Non-trauma mortality in elderly women with low bone mineral density. Lancet 1991; 338: 355-8
23. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 872-82
24. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women. Arch Intern Med 1999; 159: 1215-20 (Pubitemid 29269861)
25. Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007; 297: 387-94 (Pubitemid 46155800)
26. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporosis Int 2002; 13: 768-76 (Pubitemid 36336721)
27. Kanis JA, Johnell O, Oden A. The risk and burden of vertebral fractures in Sweden. Osteoporosis Int 2004; 15: 20-6 (Pubitemid 38252435)
28. Gandjour A, Weyler EJ. Cost-effectiveness of referrals to high-volume hospitals: an analysis based on a probabilistic Markov model for hip fracture surgeries. Health Care Manage Sci 2006; 9: 359-69 (Pubitemid 44736860)
29. Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9: 1-160
30. Melton LJ, ThamerM, Ray NF, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 16-23
31. Bartl R, Götte S, Hadji P, et al. Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis. Dtsch Med Wochenschr 2006; 131: 1257-62 (Pubitemid 44173951)
32. Kanis JA, Johnell O, Oden A, et al. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002; 30: 251-8 (Pubitemid 34044325)
33. De Laet CE, Van Hout BA, Burger H, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdamstudy. J Bone MinerRes 1998 Oct; 13 (10): 1587-93 (Pubitemid 28465299)
34. Durosier C, Hans D, Krieg MA, et al. Defining risk thresholds for a 10-year probability of hip fracture model that combines clinical risk factors and quantitative ultrasound: results using the EPISEM cohort. J Clin Densitom 2008 Jul-Sep; 11 (3): 397-403
35. Delmas PD, van de Langerijt L, Watts NB, et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 2005; 557-63 (Pubitemid 40393062)
36. De Laet C, Oden A, JohanssonH, et al. The impact of the use of multiple risk indicators for fracture on case-fnding strategies: a mathematical approach. Osteoporosis Int 2005; 16: 313-8 (Pubitemid 40379431)
37. Cooper C, Atkinson EJ, OFallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota 1985-1989. J Bone Miner Res 1992; 7: 221-7
38. Federal Statistical Office Germany (DESTATIS). Osteoporosis. Health Report Germany 1998 [online]. Available from URL: http://www.gbe-bund.de/gbe10/ abrechnung. prc-abr-test-logon?p-uid=gasts&p-aid=&p-knoten=FID &p-sprache=D&p-suchstring=914::Krankheitskosten [Accessed 2010 April 20].
39. Köster I, Ihle P, Schubert I. Chronic lumbal pain: prevalence and incidence based on data from the statutory health insurance. J Public Health 2005; 13 (Suppl. 1): S89
40. Kassenärztliche Bundesvereinigung. Uniform value scale (2006) [online]. Available from URL: http://www.ebm 2000plus.de/EBMGesamt.htm [Accessed 2009 Dec 11].
41. German red list (2006) [online]. Available from URL: http:// www.rote-liste.de [Accessed 2009 Dec 11]
42. Physio.de Informationsdienste GmbH. Catalogue of nonphysician treatments (2004) [online]. Available from URL: http://www.heilmittelkatalog.de [Accessed 2009 Dec 19]
43. Physio.de Informationsdienste GmbH. Price lists (2004) [online]. Available from URL: http://www.physio.de/pre islisten/index.php?mode= 0&PHPSESSID=188e9d915ddd0 df45f16ab93237473fe [Accessed 2009 Jan 19]
44. Institut für das Entgeltsystem im Krankenhaus (InEK). Fallpauschalen-Katalog (2006) [online]. Available from URL: http://www.g-drg.de/ cms/index.php/inek-site-de/ Archiv/Systemjahr-2006-bzw.-Datenjahr-2004#sm2 [Accessed 2009 Jan 28]
45. Institut für das Entgeltsystem im Krankenhaus (InEK). Abschlussbericht zur Weiterentwicklung des G-DRGSystems für das Jahr 2004. Klassifikation, Katalog und Bewertungsrelationen. Band II: Fallpauschalenkatalog, klinische Profile, Kostenprofile [online]. Available from URL: http://www.g-drg.de/cms/index.php/inek-site-de/ Archiv/Systemjahr-2004- bzw.-Datenjahr-2002#sm7 [Accessed 2009 Jan 28]
46. Federal Statistical Office Germany (DESTATIS). Krankheitskosten 2002, 2004 und 2006 [online]. Available from URL: https://www-ec.destatis.de/csp/shop/ sfg/bpm.html.cms. cBroker.cls?cmspath=struktur,vollanzeige.csp&ID=10224 98 [Accessed 2008 Oct 7]
47. Tosteson ANA, Jönsson B, Grima DT, et al. Challenges for model-based economic evaluations of post-menopausal osteoporosis interventions. Osteoporosis Int 2001; 12: 849-57 (Pubitemid 33086272)
48. Cramer JA, Roy A, Burrel A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-7 (Pubitemid 351160875)
49. Tidermark J, Zethraeus N, Svensson O, et al. Femoral neck fractures in the elderly: functional outcome and quality of life according to EuroQol. Qual Life Res 2002; 11: 473-81 (Pubitemid 34666526)
50. Marshall D, Johnell O, Wedel H.Meta-analysis of how well measures of bone mineral density predict occurrance of osteoporotic fractures. Br Med J 1996; 312: 1254-9 (Pubitemid 26147662)
51. Federal Statistical Office Germany (DESTATIS). Population [online]. Available from URL: http://www.destatis. de/jetspeed/portal/cms/Sites/destatis/ Internet/DE/Content/ Statistiken/Bevoelkerung/Bevoelkerungsstand/Tabellen/Con tent50/GeschlechtStaatsangehoerigkeit,templateId=render Print.psml [Accessed 2011 May 19].
52. Federal Statistical Office Germany (DESTATIS). Health in Germany [online]. Available from URL: http://www. gbe-bund.de/gbe10/owards.prc-show-pdf? p-id=9965&p- sprache=E&p-uid=gastd&p-aid=68474622&p-lfd-nr=1 [Accessed 2009 Jan 14]
53. Gandjour A, Stock S. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy 2007; 83 (2-3): 257-67 (Pubitemid 47259206)
54. Häussler B, Gothe H, Göl D, et al. Epidemiology, treatment and costs of osteoporosis in Germany: the BoneEVA Study. Osteoporos Int 2007 Jan; 18 (1): 77-84.
55. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007 Mar; 120 (3): 251-6 (Pubitemid 46341156)
56. Myers TA, Briffa NK. Secondary and tertiary prevention in the management of low-trauma fracture. Aust J Physiother 2003; 49 (1): 25-9 (Pubitemid 36321972)
57. Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ 2000; 163 (7): 819-22
58. van Staa TP, Kanis JA, Geusens P, et al. The costeffectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. Value Health 2007; 10: 348-57 (Pubitemid 47481106)
59. Stevenson M, Davis S, Lloyd-Jones M, et al. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.Health Technol Assess 2007; 11: 1-134
60. Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly costeffective for elderly women. J Am Geriatr Soc 2005 Oct; 53 (10): 1697-704 (Pubitemid 43109932)
61. Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006 Feb; 99 (2): 123-31
62. Mobley LR, Hoerger TJ, Wittenborn JS, et al. Costeffectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 2006 Mar-Apr; 26 (2): 194-206
63. Hiligsmann M, Gathon HJ, Bruyère O, et al. Costeffectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 2010;13 (4): 394-401
64. Ström O, Borgström F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries: an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007 Aug; 18 (8): 1047-61 (Pubitemid 47020004)
65. Federal Statistical Office Germany (DESTATIS). Statistisches Jahrbuch 2007 [online]. Available from URL: http://www.destatis.de/jetspeed/portal/cms/ Sites/destatis/ Internet/DE/Content/Statistiken/Arbeitsmarkt/Sozialversi cherungspflichtige/Tabellen/Content50/Altersgruppen,tem plateId=renderPrint.psml [Accessed 2010 Apr 20]
66. Barondess JA. Toward reducing the prevalence of chronic disease: a life course perspective on health preservation. Perspect Biol Med 2008 Autumn; 51 (4): 616-28
67. Munch S, Shapiro S. The silent thief: osteoporosis and womens health care across the life span. Health SocWork 2006 Feb; 31 (1): 44-53 (Pubitemid 44341471)
68. Maciosek MV, Coffield AB, Edwards NM, et al. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med 2006; 31 (1): 52-61 (Pubitemid 43956597)
69. Glasgow RE, Orleans CT, Wagner EH. Does the chronic care model serve also as a template for improving prevention? Milbank Q 2001; 79: 579-612, iv-v
70. SGB IX Sozialgesetzbuch Rehabilitation und Teilhabe behinderter Menschen [online]. Available from URL: http:// www.sozialgesetzbuch- bundessozialhilfegesetz.de/-buch/ sgb-ix.htm [Accessed 2010 May 15]